372 related articles for article (PubMed ID: 28319448)
1. Rationale and Design of a Phase 1 Clinical Trial to Evaluate HSV G207 Alone or with a Single Radiation Dose in Children with Progressive or Recurrent Malignant Supratentorial Brain Tumors.
Waters AM; Johnston JM; Reddy AT; Fiveash J; Madan-Swain A; Kachurak K; Bag AK; Gillespie GY; Markert JM; Friedman GK
Hum Gene Ther Clin Dev; 2017 Mar; 28(1):7-16. PubMed ID: 28319448
[TBL] [Abstract][Full Text] [Related]
2. Design and Rationale for First-in-Human Phase 1 Immunovirotherapy Clinical Trial of Oncolytic HSV G207 to Treat Malignant Pediatric Cerebellar Brain Tumors.
Bernstock JD; Bag AK; Fiveash J; Kachurak K; Elsayed G; Chagoya G; Gessler F; Valdes PA; Madan-Swain A; Whitley R; Markert JM; Gillespie GY; Johnston JM; Friedman GK
Hum Gene Ther; 2020 Oct; 31(19-20):1132-1139. PubMed ID: 32657154
[TBL] [Abstract][Full Text] [Related]
3. Stereotactic Placement of Intratumoral Catheters for Continuous Infusion Delivery of Herpes Simplex Virus -1 G207 in Pediatric Malignant Supratentorial Brain Tumors.
Bernstock JD; Wright Z; Bag AK; Gessler F; Gillespie GY; Markert JM; Friedman GK; Johnston JM
World Neurosurg; 2019 Feb; 122():e1592-e1598. PubMed ID: 30481622
[TBL] [Abstract][Full Text] [Related]
4. Oncolytic virus therapy using genetically engineered herpes simplex viruses.
Todo T
Front Biosci; 2008 Jan; 13():2060-4. PubMed ID: 17981691
[TBL] [Abstract][Full Text] [Related]
5. Oncolytic HSV-1 G207 Immunovirotherapy for Pediatric High-Grade Gliomas.
Friedman GK; Johnston JM; Bag AK; Bernstock JD; Li R; Aban I; Kachurak K; Nan L; Kang KD; Totsch S; Schlappi C; Martin AM; Pastakia D; McNall-Knapp R; Farouk Sait S; Khakoo Y; Karajannis MA; Woodling K; Palmer JD; Osorio DS; Leonard J; Abdelbaki MS; Madan-Swain A; Atkinson TP; Whitley RJ; Fiveash JB; Markert JM; Gillespie GY
N Engl J Med; 2021 Apr; 384(17):1613-1622. PubMed ID: 33838625
[TBL] [Abstract][Full Text] [Related]
6. A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses.
Markert JM; Razdan SN; Kuo HC; Cantor A; Knoll A; Karrasch M; Nabors LB; Markiewicz M; Agee BS; Coleman JM; Lakeman AD; Palmer CA; Parker JN; Whitley RJ; Weichselbaum RR; Fiveash JB; Gillespie GY
Mol Ther; 2014 May; 22(5):1048-55. PubMed ID: 24572293
[TBL] [Abstract][Full Text] [Related]
7. Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma.
Patel DM; Foreman PM; Nabors LB; Riley KO; Gillespie GY; Markert JM
Hum Gene Ther Clin Dev; 2016 Jun; 27(2):69-78. PubMed ID: 27314913
[TBL] [Abstract][Full Text] [Related]
8. Enhanced Sensitivity of Patient-Derived Pediatric High-Grade Brain Tumor Xenografts to Oncolytic HSV-1 Virotherapy Correlates with Nectin-1 Expression.
Friedman GK; Bernstock JD; Chen D; Nan L; Moore BP; Kelly VM; Youngblood SL; Langford CP; Han X; Ring EK; Beierle EA; Gillespie GY; Markert JM
Sci Rep; 2018 Sep; 8(1):13930. PubMed ID: 30224769
[TBL] [Abstract][Full Text] [Related]
9. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial.
Markert JM; Medlock MD; Rabkin SD; Gillespie GY; Todo T; Hunter WD; Palmer CA; Feigenbaum F; Tornatore C; Tufaro F; Martuza RL
Gene Ther; 2000 May; 7(10):867-74. PubMed ID: 10845725
[TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of oncolytic HSV-1 G207 inoculated into the cerebellum of mice.
Bernstock JD; Vicario N; Li R; Nan L; Totsch SK; Schlappi C; Gessler F; Han X; Parenti R; Beierle EA; Whitley RJ; Aban I; Gillespie GY; Markert JM; Friedman GK
Cancer Gene Ther; 2020 Apr; 27(3-4):246-255. PubMed ID: 30918335
[TBL] [Abstract][Full Text] [Related]
11. Treatment of progressive or recurrent pediatric malignant supratentorial brain tumors with herpes simplex virus thymidine kinase gene vector-producer cells followed by intravenous ganciclovir administration.
Packer RJ; Raffel C; Villablanca JG; Tonn JC; Burdach SE; Burger K; LaFond D; McComb JG; Cogen PH; Vezina G; Kapcala LP
J Neurosurg; 2000 Feb; 92(2):249-54. PubMed ID: 10659011
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of ganciclovir-mediated enhancement of the antitumoral effect in oncolytic, multimutated herpes simplex virus type 1 (G207) therapy of brain tumors.
Todo T; Rabkin SD; Martuza RL
Cancer Gene Ther; 2000 Jun; 7(6):939-46. PubMed ID: 10880026
[TBL] [Abstract][Full Text] [Related]
13. Enhanced cytotoxicity with a novel system combining the paclitaxel-2'-ethylcarbonate prodrug and an HSV amplicon with an attenuated replication-competent virus, HF10 as a helper virus.
Ishida D; Nawa A; Tanino T; Goshima F; Luo CH; Iwaki M; Kajiyama H; Shibata K; Yamamoto E; Ino K; Tsurumi T; Nishiyama Y; Kikkawa F
Cancer Lett; 2010 Feb; 288(1):17-27. PubMed ID: 19604626
[TBL] [Abstract][Full Text] [Related]
14. Viral shedding and biodistribution of G207, a multimutated, conditionally replicating herpes simplex virus type 1, after intracerebral inoculation in aotus.
Todo T; Feigenbaum F; Rabkin SD; Lakeman F; Newsome JT; Johnson PA; Mitchell E; Belliveau D; Ostrove JM; Martuza RL
Mol Ther; 2000 Dec; 2(6):588-95. PubMed ID: 11124059
[TBL] [Abstract][Full Text] [Related]
15. First-in-Human Intravenous Seprehvir in Young Cancer Patients: A Phase 1 Clinical Trial.
Streby KA; Currier MA; Triplet M; Ott K; Dishman DJ; Vaughan MR; Ranalli MA; Setty B; Skeens MA; Whiteside S; Yeager ND; Haworth KB; Simpson K; Conner J; Cripe TP
Mol Ther; 2019 Nov; 27(11):1930-1938. PubMed ID: 31570234
[TBL] [Abstract][Full Text] [Related]
16. Combination vascular delivery of herpes simplex oncolytic viruses and amplicon mediated cytokine gene transfer is effective therapy for experimental liver cancer.
Zager JS; Delman KA; Malhotra S; Ebright MI; Bennett JJ; Kates T; Halterman M; Federoff H; Fong Y
Mol Med; 2001 Aug; 7(8):561-8. PubMed ID: 11591892
[TBL] [Abstract][Full Text] [Related]
17. Oncolytic HSV-1 for the treatment of brain tumours.
Markert JM; Parker JN; Buchsbaum DJ; Grizzle WE; Gillespie GY; Whitley RJ
Herpes; 2006 Nov; 13(3):66-71. PubMed ID: 17147910
[TBL] [Abstract][Full Text] [Related]
18. Active immunotherapy: oncolytic virus therapy using HSV-1.
Todo T
Adv Exp Med Biol; 2012; 746():178-86. PubMed ID: 22639168
[TBL] [Abstract][Full Text] [Related]
19. Stereotactic injection of herpes simplex thymidine kinase vector producer cells (PA317-G1Tk1SvNa.7) and intravenous ganciclovir for the treatment of progressive or recurrent primary supratentorial pediatric malignant brain tumors.
Kun LE; Gajjar A; Muhlbauer M; Heideman RL; Sanford R; Brenner M; Walter A; Langston J; Jenkins J; Facchini S
Hum Gene Ther; 1995 Sep; 6(9):1231-55. PubMed ID: 8527482
[TBL] [Abstract][Full Text] [Related]
20. Pediatric medulloblastoma xenografts including molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex viruses.
Friedman GK; Moore BP; Nan L; Kelly VM; Etminan T; Langford CP; Xu H; Han X; Markert JM; Beierle EA; Gillespie GY
Neuro Oncol; 2016 Feb; 18(2):227-35. PubMed ID: 26188016
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
